A review of caregiver costs included in cost-of-illness studies.


Journal

Expert review of pharmacoeconomics & outcomes research
ISSN: 1744-8379
Titre abrégé: Expert Rev Pharmacoecon Outcomes Res
Pays: England
ID NLM: 101132257

Informations de publication

Date de publication:
Oct 2022
Historique:
pubmed: 25 5 2022
medline: 6 10 2022
entrez: 24 5 2022
Statut: ppublish

Résumé

Economic evaluations typically focus solely on patient-specific costs with economic spillovers to informal caregivers less frequently evaluated. This may systematically underestimate the burden resulting from disease. Cost-of-illness (COI) analyses that identified costs borne to caregiver(s) were identified using PubMed and Embase. We extracted study characteristics, clinical condition, costs, and cost methods. To compare caregiver costs reported across studies, estimated a single 'annual caregiver cost' amount in 2021 USD. A total of 51 studies met our search criteria for inclusion with estimates ranging from $30 - $86,543. The majority (63%, 32/51) of studies estimated caregiver time costs with fewer studies reporting productivity or other types of costs. Caregiver costs were frequently reported descriptively (69%, 35/51), with fewer studies reporting more rigorous methods of estimating costs. Only 27% (14/51) of studies included used an incremental analysis approach for caregiver costs. In a subgroup analysis of dementia-focused studies (n = 16), we found the average annual cost of caregiving time for patients with dementia was $30,562, ranging from $4,914 to $86,543. We identified a wide range in annual caregiver cost estimates, even when limiting by condition and cost type.

Identifiants

pubmed: 35607780
doi: 10.1080/14737167.2022.2080056
doi:

Types de publication

Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1051-1060

Auteurs

T Joseph Mattingly (TJ)

Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
The PATIENTS Program, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.

Valeria Diaz Fernandez (V)

Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.

Dominique Seo (D)

Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.

Andrea I Melgar Castillo (AI)

Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
The PATIENTS Program, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH